Madrigal Pharmaceuticals stock rises on MASH drug hopes

Shares of Madrigal Pharmaceuticals (MDGL) jumped after Novo Nordisk (NVO) said a study showed its weight-loss drug Wegovy helped people with a fatty liver disease called MASH. Madrigal has its own MASH treatment. Analysts expect the Wegovy news to have a lot of impact. First, it helps raise awareness of the disease. They also point out that Madrigal's treatment could solve certain problems related to the disease that Wegovy cannot solve.

Market Domination Anchors Julie Hyman and Josh Lipton discuss the news in the video above.

For more expert insights and analysis on the latest market activity, check out Market Domination here.

This post was written by Stephanie Mikulich.